Core Viewpoint - The Chinese beauty industry is undergoing a significant transformation from a focus on "function" to "value," driven by changes in consumer behavior and preferences [1][11]. Company Overview - Meili Tianyuan Medical Health Industry Co., Ltd. has developed over 33 years to become a leading enterprise in the Chinese beauty industry, successfully listing on the capital market and completing strategic acquisitions of the second and third largest beauty service brands in China, Nairui'er and Siyuanli [1][9]. Industry Trends - The beauty industry is experiencing a shift towards "self-pleasure consumption," where modern women prioritize inner beauty and health over mere functional needs, reflecting a deeper pursuit of value [11][18]. - The "Middle-aged Women Era" is emerging, characterized by economic independence and heightened self-awareness among women, leading to a focus on emotional value in consumption [11][12]. Strategic Initiatives - The company has outlined three major strategies for future growth: Super Brand, Super Chain, and Super Digitalization, aiming to redefine high-end beauty services and enhance customer experience [13][14]. - The Super Brand strategy focuses on establishing a new paradigm for beauty and health living, while the Super Chain strategy aims to maximize service accessibility and operational efficiency across major cities in China [13][14]. - The Super Digitalization strategy involves significant investment in technology, including the development of an AI assistant to enhance service delivery and operational efficiency [14][15]. Shareholder Value Enhancement - The company has launched a capital market value enhancement plan, committing up to 1.2 billion HKD over the next three years to increase dividends and optimize shareholder structure, reflecting confidence in its growth potential and financial stability [16][17]. Industry Outlook - The beauty industry is seen as a golden opportunity for women’s self-expression and lifestyle enhancement, with ongoing trends in branding, chain operations, and digitalization driving the sector towards a "refined era" [18].

智通财经APP获悉，开源证券发布研报称，考虑美丽田园医疗健康(02373)坚定"内生+外延"双轮驱动战 略，清晰的战略路径有望重塑美业价值新空间，该行上调盈利预测，预计公司2025-2027年归母净利润 为3.42/4.36/4.91亿元（原值为3.10/4.06/4.72亿元），对应EPS为1.36/1.73/1.95元，当前股价对应PE为 18.0/14.1/12.5倍，维持"买入"评级。 开源证券主要观点如下： 公司发布正面盈利预告，预计2025年净利润同比增长不低于34% 公司发布业绩预告：2025年预计实现收入不少于30亿元（同比+16%及以上），经调净利润不低于3.8亿 元（同比+40%及以上）；净利润不低于3.4亿元（同比+34%及以上），业绩增长强劲，展现出穿越经 济周期的强大韧性和发展潜力。 打通"内生+外延"发展路径，高整合能力驱动规模扩张 （1）外延扩张加速：公司收购贝黎诗、奈瑞儿等优质品牌并实现成功整合，逐步完善"双美+双保健"业 务版图。其中，2025H1奈瑞儿经调净利率从收购前6.5%大幅跃升至10.4%，充分印证公司的资源整合与 运营赋能能力。此外，2025年10月15日，美丽田 ...

Core Viewpoint - The company has issued a positive profit forecast, expecting a net profit growth of no less than 34% year-on-year for 2025, demonstrating strong resilience and growth potential through its "internal + external" dual-driven strategy [1] Group 1: Financial Performance - The company anticipates achieving a revenue of no less than 3 billion yuan in 2025, representing a year-on-year increase of at least 16% [1] - Adjusted net profit is expected to be no less than 380 million yuan, reflecting a year-on-year growth of at least 40% [1] - The net profit forecast is set at no less than 340 million yuan, indicating a year-on-year increase of at least 34% [1] - The company has revised its profit forecast for 2025-2027, projecting net profits of 342 million, 436 million, and 491 million yuan respectively, with corresponding EPS of 1.36, 1.73, and 1.95 yuan [1] Group 2: Growth Strategy - The company is accelerating external expansion by acquiring high-quality brands such as Beili Shi and Nai Rui Er, successfully integrating them to enhance its business landscape [1] - The adjusted net profit margin for Nai Rui Er increased significantly from 6.5% before acquisition to 10.4% post-acquisition, showcasing the company's resource integration and operational empowerment capabilities [1] - The strategic acquisition of Si Yan Li on October 15, 2025, solidifies the company's leading position, with the number of stores exceeding 734, covering 456 high-end commercial locations in first-tier and new first-tier cities [1] - The company is capitalizing on the "self-consumption" demand of women in high-tier cities, driving same-store revenue growth and enhancing its high-margin medical business capabilities [1] Group 3: Strategic Initiatives - The company has launched a "super brand, super chain, super digitalization" strategy to reshape the beauty industry [2] - The "super brand" initiative focuses on building a differentiated competitive edge through brand recognition and consumer experience [2] - The "super chain" strategy aims to overcome the highly fragmented industry landscape by establishing "1 billion yuan revenue Clubs" in 20 core cities in China, enhancing supply chain control [2] - The "super digitalization" approach includes leveraging AI capabilities in product innovation and achieving a new member retention rate of 80% with customer acquisition costs below 2% [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6]. Core Insights - The company has released a positive earnings forecast, expecting a net profit growth of no less than 34% year-on-year for 2025, with projected revenue of at least 3 billion yuan (up 16% or more) [6]. - The company is implementing a dual-driven strategy of "internal growth + external expansion," which is expected to reshape the beauty industry's value landscape [6][7]. - The company has successfully integrated acquired brands, enhancing its operational capabilities and expanding its market presence [7]. - The strategic acquisition of brands has led to significant improvements in profitability, with net profit margins increasing post-acquisition [7]. - The company aims to establish a "super brand, super chain, and super digitalization" strategy to enhance its competitive edge and customer experience [8]. Financial Summary and Valuation Metrics - Revenue projections for 2025 are set at 3,007 million yuan, with a year-on-year growth of 16.9% [10]. - The expected net profit for 2025 is 342 million yuan, reflecting a year-on-year increase of 49.6% [10]. - The company's gross margin is projected to be 47.7% in 2025, with a net margin of 12.3% [10]. - The earnings per share (EPS) for 2025 is estimated at 1.4 yuan, with a price-to-earnings (P/E) ratio of 18.0 times [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has released a positive earnings forecast, expecting a net profit growth of no less than 34% year-on-year for 2025, with projected revenue of at least 3 billion HKD (up 16% or more) and adjusted net profit of no less than 3.8 billion HKD (up 40% or more) [6] - The company is focusing on a dual-driven strategy of "internal growth + external expansion," which is expected to reshape the value of the beauty industry [6] - The company has successfully integrated acquired brands, enhancing its operational capabilities and expanding its business footprint [7] - The company aims to establish a "super brand, super chain, and super digitalization" strategy to create new value spaces in the beauty industry [8] Financial Summary and Valuation Metrics - For 2025, the company is projected to achieve a revenue of 3,007 million HKD, representing a year-on-year growth of 16.9% [10] - The net profit for 2025 is expected to be 342 million HKD, reflecting a year-on-year increase of 49.6% [10] - The projected EPS for 2025 is 1.4 HKD, with a corresponding P/E ratio of 18.0 times [10]

Core Viewpoint - Meili Tianyuan is projected to achieve a revenue of no less than 3 billion yuan and a net profit of no less than 340 million yuan by 2025, marking the emergence of a 30 billion yuan giant in China's beauty industry [1][19]. Financial Performance - For 2025, Meili Tianyuan expects revenue to be at least 30 billion yuan, representing a growth of at least 16% compared to 2024, and an adjusted net profit of no less than 340 million yuan, reflecting a year-on-year increase of at least 34% [5][22]. - Over the past six years, the company's revenue has grown from 1.503 billion yuan in 2020 to at least 3 billion yuan in 2025, with net profit increasing from 152 million yuan to at least 340 million yuan during the same period [5][22]. Strategic Expansion - Since 2024, Meili Tianyuan has successfully acquired the top three brands in China's high-end beauty industry, including Meili Tianyuan, Nairui'er, and Siyuanli, significantly expanding its market presence [4][26]. - The company has adopted a dual growth strategy of "internal growth + external acquisitions," with plans to double revenue in five years and net profit in three years [4][21]. Market Positioning - Meili Tianyuan has identified a trend of "self-consumption" among women in high-tier cities, effectively driving same-store revenue growth despite market challenges [9][26]. - The company has expanded its store network to over 734 locations, capturing a significant market share in 20 first-tier and new first-tier cities [9][26]. Digital Transformation - The company has invested over 200 million yuan in the past five years to build a 90-member IT team, enhancing its capabilities as a digital and intelligent chain enterprise [12][29]. - Meili Tianyuan is integrating AI into product innovation, exemplified by the AI model "AI Xiaonai," which combines extensive knowledge in traditional Chinese medicine and beauty [30]. Industry Outlook - The Chinese beauty market is expected to continue expanding, with potential for the emergence of 50 billion to 100 billion yuan enterprises as leading brands like Meili Tianyuan drive consolidation in the industry [15][33]. - Consumer willingness to spend on national brands is significantly higher than on smaller brands, indicating a strong market preference for established names [16][33].

Core Viewpoint - Meili Tianyuan Medical Health Industry Co., Ltd. forecasts a positive profit outlook for 2025, expecting revenue of at least 3 billion yuan, a year-on-year increase of no less than 16%, and adjusted net profit of at least 380 million yuan, representing a growth of no less than 40% [1] Group 1: Performance Growth Drivers - The company demonstrates strong resilience and growth potential through robust performance, attributed to two main factors: accelerated external expansion and strong internal growth momentum [2][3] - The successful acquisition of the second-largest brand in the Chinese beauty industry, Nairui'er, has significantly enhanced the company's market share and business footprint in key areas, with Nairui'er’s adjusted net profit margin increasing from 6.5% to 10.4% post-acquisition [2] - The upcoming acquisition of the third-largest beauty service brand, Siyuanli, will further consolidate the top three brands under Meili Tianyuan, expanding its store network to over 734 locations [2] Group 2: Strategic Initiatives - The company is focusing on the "self-consumption" upgrade trend among women in high-tier cities, effectively driving same-store revenue growth [3] - Meili Tianyuan plans to implement three major strategic initiatives: Super Brand, Super Chain, and Super Digitalization, aiming to redefine high-end beauty services and reshape industry value [3] - The company will continue to pursue a dual-driven growth strategy of "internal growth + external acquisitions," enhancing its "dual beauty + dual health" business model to create sustainable value for customers, shareholders, employees, and partners [3]

Core Viewpoint - The acquisition of 100% equity in Shanghai Siyuanli Industrial Co., Ltd. by Meili Tianyuan for 1.25 billion yuan is expected to enhance the group's market position and financial performance, contributing to sustained revenue and profit growth for investors [1][2]. Group 1: Acquisition Details - The acquisition was completed on January 7, 2026, and Siyuanli is now a wholly-owned subsidiary of Meili Tianyuan, with its financial results integrated into the group's consolidated financial statements [1]. - Siyuanli achieved a revenue of 850 million yuan and a net profit of 81 million yuan in 2024, indicating its strong operational performance [2]. - Following the acquisition, the total number of the group's stores has expanded to 734, enhancing its market influence [1]. Group 2: Strategic Synergies - Both Meili Tianyuan and Siyuanli operate in 20 major cities, with over 60% of total revenue coming from first-tier cities like Beijing, Shanghai, Guangzhou, and Shenzhen [2]. - The acquisition will integrate approximately 60,000 direct members from Siyuanli into the group's membership system, resulting in a 44% increase in active membership [2]. Group 3: Future Growth Strategies - The group plans to leverage its experience from the acquisition of the second-largest brand, Nairui, to drive Siyuanli's revenue and efficiency growth through systematic output of medical beauty and sub-health services [3]. - The company aims to implement three major strategies: "super brand," "super chain," and "super digitalization," focusing on personalized customer experiences and operational efficiency [3]. - The introduction of AI capabilities into product innovation is a key aspect of the group's strategy, with plans to launch the "Nairui Intelligent Beauty AI" by 2025 [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation of performance relative to the market [4]. Core Insights - The company is focusing on a dual-driven strategy of organic growth and acquisitions, with a particular emphasis on three major strategic areas: Super Brand, Super Chain, and Super Digitalization [6]. - The acquisition of 100% of the shares of Siyanli for 1.25 billion RMB (approximately 1.369 billion HKD) is expected to enhance market share and accelerate the company's strategic layout [4]. - The company has increased its stake in Nairui to 90%, with significant improvements in operational efficiency post-acquisition, reflected in a rise in adjusted net profit margin from 6.5% to 10.4% [5]. Financial Data and Earnings Forecast - The company forecasts revenue growth from 2,145 million RMB in 2023 to 4,541 million RMB in 2027, with a compound annual growth rate (CAGR) of approximately 31.16% [8]. - Adjusted net profit is projected to increase from 241 million RMB in 2023 to 540 million RMB in 2027, with a notable growth rate of 53.18% in 2023 [8]. - The adjusted earnings per share (EPS) is expected to rise from 1.05 RMB in 2023 to 2.29 RMB in 2027, reflecting a strong upward trend in profitability [8].

Investment Rating - The report assigns an "Outperform" rating to Beauty Farm Medical and Health Industry, expecting a relative return exceeding 10% over the next 12-18 months [24]. Core Insights - Beauty Farm has articulated a clear strategy centered around the "Three Super" initiatives: Super Brand, Super Chain, and Super Digitalization, aiming to build core competitive advantages in the beauty services industry [2][9]. - The company targets to establish operational entities with revenues exceeding RMB 100 million in 20 core cities, which contribute approximately 40% of the industry revenue, with a solid foundation already in place as 8 cities have achieved this target [3][10]. - Recent operational performance shows strong momentum, with same-store sales growth of 6-8% and collection growth accelerating to low double digits, indicating robust endogenous growth [4][11]. Summary by Sections Strategic Overview - The "Three Super" strategy focuses on enhancing brand value, expanding chain operations, and leveraging digitalization to deepen customer relationships and operational efficiency [2][9]. - The company has integrated three premium brands to secure a strong position in the high-end market and aims to enhance customer experience through personalized services [2][9]. Growth Strategy - The goal is to increase the number of cities generating over RMB 100 million in revenue from 8 to 20 in the near term, with a focus on developing Shanghai and Beijing into "super cities" with revenues exceeding RMB 1 billion each [3][10]. - The growth will be driven by both organic growth and strategic acquisitions, leveraging successful past experiences in markets like Chongqing and Xi'an [3][10]. Financial Performance - The company has demonstrated exceptional profit enhancement capabilities, with significant improvements in revenue per store and profit margins post-acquisition [4][11]. - Strong cash flow generation is projected, with estimated operating cash flow of approximately RMB 1 billion for FY25, supporting future shareholder returns and strategic acquisitions [4][11]. Industry Context - The beauty services industry in China is highly fragmented, with nearly 90% of operations being single-store, presenting significant opportunities for consolidation driven by branding, chainification, and digitalization [5][12]. - The company anticipates a decrease in the total number of industry stores, while the market share and profitability of leading players with strong branding and digital capabilities will increase significantly [5][12]. M&A Strategy - Proven M&A integration capabilities are a key engine for executing the Super Chain strategy, with over 30 successful transactions completed historically [6][13]. - The recent integration of Naturade has validated the effectiveness of the company's platform-based empowerment model, with expectations of similar success from the newly acquired DECLÉOR [6][13].